The acquisition is a strategic pipeline expansion into a rare disease with high unmet need and commercial precedent (Jynarque's $1.5B sales). With a clear development path starting in late 2026 and low upfront cost relative to potential upside, this could re-rate SCYX's valuation if early data is positive. Traders should monitor the Phase 2 initiation in Q4 2026 and watch for enrollment updates as catalysts.
SCYX drugs
SCYX drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 31 $7.34entry
- T+1 · 8mo ago −3.16%α −3.92% · $7.10
- T+5 · 7mo ago +8.62%α +4.67% · $7.97
- T+20 · 7mo ago +1.85%α −7.56% · $7.47
- T+60 · 5mo ago −47.52%α −59.90% · $3.85
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Scynexis (SCYX) announced the acquisition of PXL-770 (now SCY-770), a clinical-stage oral therapy for autosomal dominant polycystic kidney disease (ADPKD), from Poxel S.A. The deal includes an $8 million upfront payment, $8 million in potential development milestones, and up to $180 million in commercial milestones. SCY-770, a novel AMPK activator with orphan drug designation, is expected to enter a Phase 2 proof-of-concept study in Q4 2026, positioning Scynexis to expand into a high-unmet-need rare disease market.
Key Financial Metrics
Key Facts
- Scynexis acquired SCY-770 (formerly PXL-770) from Poxel S.A. for $8M upfront and up to $196M in total milestones ($8M development + $180M commercial).
- SCY-770 is a novel, oral, direct AMPK activator with orphan drug designation for ADPKD, a rare genetic kidney disease with limited treatment options.
- Phase 2 proof-of-concept study in ADPKD patients expected to start in Q4 2026, with early efficacy readout in second half of 2027.
- Current ADPKD market has only one approved therapy (Jynarque), which had ~$1.5B in U.S. sales in 2024 despite limited uptake.
- Scynexis has potential to receive up to $146M in annual sales milestones and low-to-mid-single-digit royalties from GSK on Brexafemme.
Financial Impact
$8 million upfront cash payment, $8 million in potential development milestones, and up to $180 million in commercial milestones based on sales performance
Risk Factors
- SCY-770 is still pre-clinical for ADPKD; efficacy in this indication is unproven despite prior safety data in NAFLD.
- Scynexis has limited cash resources; future funding needs could lead to dilution.
- Milestones are contingent on clinical and commercial success, high risk given early stage.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3265277 |
Track record
14 reports on SCYX
4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +33.49% at T+20 after the May 11, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.91 Now $2.91 +0.00% settles Nov 24
- Nov 5, 202611d ago S-3 Neutral 3/10 Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
- Oct 22, 202625d ago Press Release Bullish 7/10 Entry $3.81 to $3.86 Now $2.91 −23.62% ▲ +1.31% +0.61% vs SPY
- Oct 6, 20265w ago Press Release Neutral 4/10 Entry $4.84 to $3.99 Now $2.91 −39.88% ▼ −17.56% −17.42% vs SPY
- Sep 28, 20267w ago Press Release Bullish 6/10 Entry $4.62 to $5.03 Now $2.91 −37.01% ▲ +8.87% +7.67% vs SPY
- Sep 22, 20267w ago 8-K Neutral 2/10 Entry $4.86 to $4.66 Now $2.91 −40.12% ▼ −4.12% −2.93% vs SPY
- Sep 10, 20269w ago 8-K Neutral 2/10 Entry $4.70 to $4.45 Now $2.91 −38.09% ▼ −5.32% −4.82% vs SPY
- Jun 26, 202620w ago 8-K Neutral 3/10 Entry $3.87 to $4.73 Now $2.91 −24.81% ▲ +22.22% +20.83% vs SPY
- May 22, 202625w ago 8-K Neutral 4/10 Entry $5.45 to $5.33 Now $2.91 −46.59% ▼ −2.17% −3.25% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers